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To the Editor:
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a
rare dermatopathic hematological malignancy derived from
plasmacytoid dendritic cell (pDC) precursors. It co-exists
with other myeloid malignancies in >20% of cases, and
especially frequently with chronic myelomonocytic leuke-
mia (CMML) [1]. Given emerging data for shared clonal
origin [2, 3] and supportive clonal pDCs characterizing the
CMML microenvironment [4], these diseases might share
common biology and therapeutic vulnerabilities. However,
their detailed genomic landscape, clonal relationship, and
distinctive pathogenesis remain unclear.
A 73-year-old male presented with widespread purpuric
lesions over trunk and limbs (Supplementary Fig. 1). Ten
years earlier he was diagnosed with low-risk CMML-0,
managed throughout by active surveillance. Skin biopsy
confirmed BPDCN, with infiltration by moderately
proliferative (Ki67 50%) blasts expressing the classic
diagnostic triad of CD4, CD56, and CD123 [1], alongside
BCL2, CD10, CD33, TdT, and CD99. Blood count revealed
a stable monocytosis (1.4 × 109/L) and neutropenia (1.4 ×
109/L), but a normal platelet count. Bone marrow (BM)
was heavily infiltrated by CMML, with hypercellular,
dysplastic myelomonocytic precursors but no blast/promo-
nocyte excess. Flow cytometry of BM revealed 26%
CD64+CD14+ monocytes, 1% CD34+ myeloblasts, and
1% neoplastic pDCs (CD4+CD56+CD123+HLA-DR+
NG2+), indicating low-level BPDCN involvement. Kar-
yotype was normal. Non-intensive treatment with azaciti-
dine was commenced. After three cycles skin lesions
remained unchanged. BM showed regression of CMML but
now extensive (>70%) involvement by BPDCN. Azaciti-
dine was discontinued and he was managed with supportive
care. Shortly after he developed central visual loss with
choroidal infiltrates, indicating central nervous system
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infiltration. He declined lumbar puncture and died 9 months
after BPDCN diagnosis.
Samples were collected from BM, skin and buccal swab
at BPDCN presentation, and from BM following azacitidine.
Six samples were prepared for analysis: CD34+ hemato-
poietic stem/progenitor cells (“HSPC-BM-1”), CD14+
CMML cells (“CMML-BM-1”) and CD4+CD56+CD123+
BPDCN cells (“BPDCN-BM-1”) (from presentation BM by
flow sorting); whole skin biopsy from a presenting BPDCN
lesion (“BPDCN-SK-1”); sorted BM BPDCN cells post-
azacitidine (“BPDCN-BM-2”; CD4+CD56+CD123+); and
buccal swab as germline control. All samples underwent
whole exome sequencing (WES) on the IonTorrentTM plat-
form (Fig. 1A; Supplementary Methods; Supplementary
Table 1; Supplementary Fig. 2).
In total 249 somatic variants (involving 241 genes) were
identified across the five non-germline samples, 97 invol-
ving coding regions or splice sites with predicted transla-
tional consequence (Supplementary Table 2). A TET2
p.Glu1010Ter nonsense somatic mutation was present in all
samples, with mean VAF 50.8% (range 49.8–52.3%). Five
somatic mutations were common to all samples, indicating a
shared founding clone arising within the HSPC compart-
ment and propagated across both diseases. In addition to the
TET2 mutation was a pathogenic splice site mutation in
ZRSR2, a 5′UTR variant of the E3-ubiquitin ligase TRIM4,
and passenger (noncoding/synonymous) mutations in
MYO7B and THSD7B.
Downstream, the CMML and BPDCN samples displayed
markedly different mutation profiles and evolutionary paths,
indicating early clonal divergence (Fig. 1B–D; Supplementary
Fig. 3) and disease-specific secondary driver lesions (Fig. 2).
CMML-BM-1 harbored cancer-associated mutations includ-
ing MPL p.Tyr591Asp, CHD4 p.Arg877Gln, and MAP4K3
p.Met220Val; the latter altering the kinase domain of a pro-
tein reportedly dysregulated by TET2 silencing [5]. All
CMML-BM-1 mutations were also detectable (at lower VAF)
in HSPCs, indicating malignant evolution from the TET2/
ZRSR2-mutated founding clone within the CD34+ compart-
ment. None were detected in any BPDCN specimen.
By contrast, many more genetic lesions were identified in
the BPDCN samples. SciClone resolved nine distinct
Fig. 1 Early divergent clonal evolution of CMML and BPDCN
from a shared founding clone. A Schematic of experimental setup
and samples used for whole exome sequencing from the index patient.
B Venn diagram showing the distribution of all somatic variants
identified across the five sequenced exomes (n= 249). C Phylogenetic
evolution tree for the nine distinct mutation clusters identified by
SciClone across the five sequenced exomes; clusters unique to specific
compartments are indicated in parentheses. D Composite fish plot
depicting the clonal architecture and evolution in our index patient.
Each color represents the indicated clone and aligns with color scheme
in (C); cluster numbers were automatically assigned by SciClone and
are annotated on the plot. Selected exemplar mutations for each
defined cluster are also labeled. Block arrows emphasize the distinct
evolution paths toward CMML and BPDCN, and then for the BPDCN
marrow expansion at disease progression. For enhanced clarity, the
clonal arrangement within the small BPDCN-BM-1 clone (represent-
ing 1.08% of total marrow cells by flow cytometry) is expanded within
the inset, as indicated. Similarly, the plot for the contemporaneous
presentation skin sample (BPDCN-SK-1) is inverted/transposed, to
display clonal evolution in this tissue separately from the bone
marrow-derived samples (rather than in misleading linear series).
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mutation clusters (Fig. 2). Two large clusters (C2; C3)
included mutations displaying high (~40–60%) VAF in all
three BPDCN samples, but absent from the HSPC-BM-1 or
CMML-BM-1 samples, suggesting a “secondary” BPDCN-
initiating event likely outside the CD34 compartment
and after pDC precursor egress from BM. These included
a hotspot mutation in the putative oncogene MED12






























































































Fig. 2 Mutation oncoprint
depicting all somatic coding
and pathogenic splice site
variants (n= 98) across each
of the five sequenced exomes
from the index patient.
Variants are arranged according
to mutation cluster as
determined by ClonEvol/
Sciclone (see Fig. 1C, D); color
intensity is scaled to represent
variant allele frequency for each
mutation.
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factor GLIS3 and Rac GTPase regulator DOCK1. SciClone
segregated mutation clusters distinct to either BPDCN-
SKIN-1 (C5) or BPDCN-BM-1 (C4; C8), indicating sub-
clonal divergence between the cutaneous and BM diseases
following recirculation back to BM (Fig. 1C, D). Only C4
was detected in (and dominated) BPDCN-BM-2, high-
lighting the subclone responsible for BPDCN progression
through azacitidine; this included COSMIC-annotated
pathogenic mutations involving CDK18 (p.Glu275Lys)
and EBF3 (p.Arg129Cys). An NRAS p.Tyr64Asn mutation
was identified in BPDCN-BM-1 only, indicating presence
in a clone outcompeted and/or suppressed by azacitidine.
HSPCs contained no high-confidence CNVs. By con-
trast, all BPDCN samples displayed a significant CNV
burden, indicating relative genomic instability. These all
harbored a ~5Mb deletion at chromosome 12p13.31
encompassing 72 genes, including ETV6 and others with
documented roles in DC migration/function (Supplementary
Fig. 4). Accordingly, BM cytogenetics post-azacitidine
confirmed add(12)(p11.2) and ETV6 loss by FISH in 56/100
cells (Supplementary Fig. 5). Other CNVs were private to
individual samples, indicating later subclonal events (Sup-
plementary Fig. 4). These included several regions of copy
gain across chr12 (BPDCN-BM-1); trisomies 2 and 7
(BPDCN-SK-1); chr20 gain and deletions involving the
TNF receptor-associated TRAF7 and MTOR-associated
protein MLST8 (ch16p13.3) (BPDCN-BM-2).
A shared clonal origin of CMML and BPDCN has been
proposed previously. Targeted sequencing of a similar
patient found TET2 and SRSF2 mutations in both BM
MNCs and contemporaneous skin biopsy, indicating these
as shared early events. JAK2 was mutated exclusively in
BM as a presumed CMML-specific subclonal event [2].
Another case reported WES on unsorted BM MNCs from
CMML presentation and later at BPDCN, again demon-
strating shared ancestry (including a TET2 mutation) whilst
implicating biallelic RB1 loss in BPDCN transformation [3].
This implied BPDCN transforming directly from CMML,
through acquisition of additional genetic lesions.
Ours is the first study to directly partition CMML and
BPDCN from the same compartment, and to sequence (at
exome level) sorted subpopulations from different sites and
timepoints. We too demonstrate shared initiation, but with
remarkably distinct subsequent evolutionary paths in a
complex genomic landscape. Again, TET2 loss-of-function
was a shared ancestral event, mirroring its known recur-
rence in both diseases [6, 7]. For the first time we collated
20 cases of BPDCN co-existing with CMML (or its pre-
cursor clonal hematopoietic states), including several pre-
viously unpublished (Supplementary Table 3). Remarkably,
TET2 was mutated in 13/13 (100%) of sequenced cases,
implying ubiquity in this context and significantly higher
frequency versus reported series of unselected BPDCN
(p= 0.0002; Fisher’s exact test; Supplementary Fig. 6). The
divergent phylogenetic paths in our patient epitomize the
promiscuous malignant potential of TET2 dysfunction, and
the influence of cellular context and secondary lesions in
modulating resultant malignant phenotype. This reconciles
with observations in murine models, in which Tet2 loss
biased HPSCs toward production of both macrophages and
DCs, from distinct multipotent progenitor populations,
establishing discrete foundations for both diseases [8].
No BPDCN-exclusive mutations were detected in the CD34
+ compartment. Thus, although rooted in a preleukemic
HSPC, BPDCN transformation occurred via a “secondary”
initiation event in a more committed cell, in keeping with its
typically CD34-negative immunophenotype [1]. A core set of
shared mutations across all BPDCN samples implicates the
minor BPDCN-BM-1 population as part of the malignant
clone, rather than a benign clonal pDC expansion (a docu-
mented feature in CMML-BM [4]). Relative disease propor-
tions in BM and skin suggest extramedullary initiation with
subclonal recirculation back to BM. Subsequently one BPDCN
subclone outcompeted the other, synchronous with regression
of the CMML (also outcompeted, or eradicated by azacitidine).
The most prominent BPDCN-specific lesion was ETV6
loss, conclusively lacking from CMML cells so precluding
detection on initial BM cytogenetics. ETV6 encodes an ETS
family transcription factor that is a key regulator of HSPC
function and tumor suppressor. ETV6 disruption was recently
linked to BPDCN [9, 10], with 12p karyotypic abnormalities
commonly seen [1]. We also identifiedMED12 p.Gly44Ser in
BPDCN for the first time, as a novel candidate “secondary”
driver mutation. This hotspot mutation occurs frequently
(~70–80%) in uterine leiomyoma and breast fibroepithelial
tumors (plus their malignant equivalents), 5–10% of chronic
lymphocytic leukemias, and sporadically in other cancers
[11]. Intriguingly, the highest MED12 expression in hema-
topoiesis is reportedly in pDCs (Supplementary Fig. 7), and it
is prominently induced upon ex vivo DC activation [12],
indicating functional importance in DCs.
MED12 encodes a kinase module of the transcriptional
coactivator Mediator complex, conveying signals from
chromatin-bound transcription factors at enhancers through
recruitment of RNAPII to promoters. Oncogenic Gly44
mutations impair MED12’s ability to activate CDK8 and
CDK19, dysregulating key transcriptional networks [13]. They
are tumorigenic in murine models, mediating widespread
genomic instability [14]. Notably, TP53, CDKN2A and RB1
inactivation, prominent inducers of genomic instability and
common in BPDCN, were absent in our patient. MED12
mutations might phenocopy these and represent an alternative
route to genomic instability: a fundamental intermediate event
in BPDCN pathogenesis. InterestinglyMED12 is X-linked, and
not confirmed to escape X-inactivation; if Gly44 substitutions
confer tumorigenic gain-of-function as has been proposed [14]
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this could further contribute to BPDCN’s striking (~3:1) male
preponderance.
We investigated whether MED12 mutations are recurrent
in BPDCN. Few suitable existing BPDCN sequencing data-
sets were identified. We reviewed four published [3, 15] and
two unpublished BPDCN-BM exomes, plus eight BM sam-
ples sequenced by a 300-gene panel [7]. We also sequenced
MED12 exons 1–2 in 15 archived BM and 9 skin biopsies,
validating the mutation in our index patient but finding no
others in this limited cohort (Supplementary Fig. 8). None-
theless, our study highlights this well-described oncogenic
mutation as a novel potential BPDCN driver downstream of
the apparently ubiquitous TET2-mutant foundation for this
important clinical association.
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